Echo IQ Launches EchoSolv in the US
- Echo IQ (EIQ) releases EchoSolv, its cloud-based enhanced screening platform for structural heart disease, in the US
- EchoSolv has been developed and “rigorously tested” in consultation with leading cardiologists, the company says
- The product is designed to support clinicians and physicians in identifying patients with guideline-defined aortic stenosis
- Chief Commercial Officer Deon Strydom says the launch is an important step in the US and the company is looking to deploying at several leading hospitals and health systems
- Shares in EchoIQ closed at 19 cents on Wednesday afternoon
